Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Glioblastoma stem cells after treatment with sulconazole.

ABSTRACT: Glioblastoma stem cells after treatment with sulconazole.

PROVIDER: PRJNA628508 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR11611474_1.fastq.gz	Fastqsanger.gz
	SRR11611474_2.fastq.gz	Fastqsanger.gz
	SRR11611475_1.fastq.gz	Fastqsanger.gz
	SRR11611475_2.fastq.gz	Fastqsanger.gz
	SRR11611476_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Abernathy2016 - glioblastoma treatment

Project description:The paper describes a model of glioblastoma. Created by COPASI 4.25 (Build 207) This model is described in the article: Modeling the Treatment of Glioblastoma Multiforme and Cancer Stem Cells with Ordinary Differential Equations Kristen Abernathy and Jeremy Burke BMC Computational and Mathematical Methods in Medicine Volume 2016, Article ID 1239861, 11 pages Abstract: Despite improvements in cancer therapy and treatments, tumor recurrence is a common event in cancer patients. One explanation of recurrence is that cancer therapy focuses on treatment of tumor cells and does not eradicate cancer stem cells (CSCs). CSCs are postulated to behave similar to normal stem cells in that their role is to maintain homeostasis. That is, when the population of tumor cells is reduced or depleted by treatment, CSCs will repopulate the tumor, causing recurrence. In this paper, we study the application of the CSC Hypothesis to the treatment of glioblastoma multiforme by immunotherapy. We extend the work of Kogan et al. (2008) to incorporate the dynamics of CSCs, prove the existence of a recurrence state, and provide an analysis of possible cancerous states and their dependence on treatment levels. To cite BioModels Database, please use: BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models . To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication for more information.

2024-09-02 | BIOMD0000000757 | BioModels

RNA-seq of glioblastoma stem cells with CCL21 treatment

Project description:RNA-seq of glioblastoma stem cells with CCL21 treatment

| PRJNA738513 | ENA

Glioblastoma stem-like-cells

Project description:Glioblastoma stem-like-cells

| PRJNA751558 | ENA

RNA-seq of glioblastoma stem cells with CCL21 treatment

Project description:RNA-seq of glioblastoma stem cells with CCL21 treatment

2023-08-04 | GSE178337 | GEO

RNA-seq of YY1 knockdown and alvocidib treatment in glioblastoma stem cells

Project description:RNA-seq of YY1 knockdown and alvocidib treatment in glioblastoma stem cells

2022-06-01 | GSE155836 | GEO

Glioblastoma stem cells RNAseq profiling

Project description:Glioblastoma stem cells RNAseq profiling

| PRJNA743335 | ENA

Transcriptome of glioblastoma stem cells.

Project description:Transcriptome of glioblastoma stem cells.

| PRJNA678321 | ENA

Quantitative phosphoproteome analysis of glioblastoma stem cells

Project description:Glioblastoma is one of the most malignant brain tumors with poor prognosis and their development and progression are known to be driven by glioblastoma stem cells. Although glioblastoma stem cells lose their cancer stemness properties during cultivation in serum-containing medium, little is known about the molecular mechanisms regulating signaling alteration in relation to reduction of stemness. In order to elucidate the global phosphorylation-related signaling events, we performed a SILAC-based quantitative phosphoproteome analysis of serum-induced dynamics in glioblastoma stem cells established from the tumor tissues of the patient. Among a total of 2,876 phosphorylation sites on 1,584 proteins identified in our analysis, 732 phosphorylation sites on 419 proteins were regulated through the alteration of stem cell characteristics.

2016-01-13 | PXD002614 | Pride

glioblastoma and glioblastoma stem cells (GSCs), RNA-seq and WGS

Project description:Characterization of glioblastoma tumors and glioblastoma stem cells (GSCs) lines via RNA-seq and/or WGS profiling.

| EGAS00001004395 | EGA

RNA-seq of YY1 knockdown and alvocidib treatment in glioblastoma stem cells

Project description:RNA-seq of YY1 knockdown and alvocidib treatment in glioblastoma stem cells

| PRJNA655724 | ENA